Accessibility Menu
Viking Therapeutics logo

Viking Therapeutics

(NASDAQ) VKTX

Current Price$32.71
Market Cap$3.80B
Since IPO (2015)+265%
5 Year+525%
1 Year+16%
1 Month+5%

Viking Therapeutics Financials at a Glance

Market Cap

$3.80B

Revenue (TTM)

$0.00

Net Income (TTM)

-$472.34M

EPS (TTM)

-$4.15

P/E Ratio

-7.90

Dividend

$0.00

Beta (Volatility)

1.27 (Average)

Price

$32.71

Volume

1,747,727

Open

$32.25

Previous Close

$32.74

Daily Range

$31.81 - $33.16

52-Week Range

$22.96 - $43.15

VKTX: Motley Fool Moneyball Superscore

68

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Viking Therapeutics

Industry

Biotechnology

Employees

59

CEO

Brian Lian, PhD, MBA

Headquarters

San Diego, CA 92121, US

VKTX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-70%

Return on Capital

-1%

Return on Assets

-78%

Earnings Yield

-12.66%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.80B

Shares Outstanding

116.11M

Volume

1.75M

Avg. Volume

2.27M

Financials (TTM)

Gross Profit

-$431.00K

Operating Income

-$393.34M

EBITDA

-$393.34M

Operating Cash Flow

-$278.69M

Capital Expenditure

$0.00

Free Cash Flow

-$278.69M

Cash & ST Invst.

$705.74M

Total Debt

$137.00K

Viking Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$3.80B

N/A

Market Cap/Employee

$84.47M

N/A

Employees

45

N/A

Net Income

-$158.33M

-247.0%

EBITDA

-$164.13M

-196.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$602.96M

-29.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

-77.66%

N/A

Return on Invested Capital

-1.00%

N/A

Free Cash Flow

-$113.98M

-117.8%

Operating Cash Flow

-$113.98M

-117.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRNXCrinetics Pharmaceuticals, Inc.
$35.55-1.28%
ACADACADIA Pharmaceuticals Inc.
$21.66+0.14%
NAMSNewAmsterdam Pharma Company N.V.
$33.68-4.91%
AKROAkero Therapeutics, Inc.
$54.65+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCEVirgin Galactic
$6.18+0.36%
ONDSOndas
$13.22-0.00%
NOKNokia
$14.84-0.03%
TAT&T
$24.80-0.00%

Questions About VKTX

What is the current price of Viking Therapeutics?

Viking Therapeutics is trading at $32.74 per share.

What is the 52-week range for Viking Therapeutics?

Over the past 52 weeks, Viking Therapeutics has traded between $22.96 and $43.15.

How much debt does Viking Therapeutics have?

As of the most recent reporting period, Viking Therapeutics reported total debt of $0.00.

How much cash does Viking Therapeutics have on hand?

Viking Therapeutics reported $118.12M in cash and cash equivalents in its most recent financial results.

What is Viking Therapeutics’s dividend yield?

Viking Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.